Arunoday Singh-headed O-Health secures strategic funding
Executive Brief • Key Highlights
Fast factual intelligence distilled for busy investors, executives, and answer bots:
- ✓O-Health secured strategic funding from investors including Sangita Reddy and BugleRock Capital on Saturday.
- ✓The company plans to use the money to build indigenous AI models and clinical hardware.
- ✓CEO Arunoday Singh said, “The larger objective remains unchanged: making healthcare more accessible through technology that works in the world.”
Story at a Glance
- Category
- Indian Markets
- Reported By
- The Economic Times
- Reading Speed
- 3 Minute(s)
- Market Focus
- India Economy
Synopsis
O-Health has received strategic funding from several investors to advance its healthcare technology solutions. The company aims to enhance its voice-first AI-enabled clinical pre-assessment platform for better patient information management. The investment will support the expansion into additional healthcare sectors and development of indigenous AI models and clinical hardware. O-Health plans to broaden its focus to include preventive health technologies and intelligent hospital workflows.
New : O-Health, an Indian healthcare technology company building indigenous edge AI and clinical hardware, said on Saturday that it has secured strategic funding from Sangita Reddy of Apollo Hospitals, Singapore-based BugleRock Capital, Perpetual Capital led by Pranav Prashanth and Anvitha Prashanth, Varun Dua of ACKO, a Delhi-based family office, and other investors.
Unlock the Full Story with ArthNow Premium
To continue reading this complete financial story and in-depth market context, upgrade to ArthNow Premium. Enjoy unlimited access across Web and Mobile.
The Economic Times
Read the full, original unfiltered story directly on the publisher's portal.
This brief is for information only and is not investment advice. ArthNow is not a SEBI-registered investment adviser and does not publish buy or sell recommendations. Original reporting is credited to the publisher named above. Read our editorial policy or report an error.